TrialThe oncologist2022

Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.

Lori J Wirth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.